MEVAC, a leading company in the field of veterinary vaccine manufacturing in Egypt and the region, has announced the opening of its largest industrial expansion within its industrial complex in New Salhia City.

This expansion was made with massive investments exceeding EGP 3 billion during the years 2024 and 2025. It includes the establishment of the largest veterinary vaccine production facility in Africa and the Middle East, in addition to an advanced research and development center, and a center for innovation and excellence in quality.
This strategic project aims to enhance MEVAC’s capabilities in veterinary vaccine production. Following this expansion, the company will be able to produce more than 12 billion doses of poultry vaccines and over 120 million doses of ruminant vaccines annually. The company’s third factory, located within the industrial complex, has been equipped with the latest automated production lines to ensure high efficiency and quality and to meet the growing global demand for veterinary vaccines.
The opening ceremony witnessed high-level official attendance, led by Eng. Hazem Al-Ashmouny, Governor of Sharqia; Dr. Tarek Suleiman, Head of the Livestock and Poultry Development Sector; Dr. Hamed Al-Aqnas, Chairman of the General Authority for Veterinary Services; and Major General Yasser Abbas, Deputy CEO of the General Authority for Investment. Also in attendance were Dr. Magdy El-Sayed, Chairman of MEVAC; Dr. Ahmed El-Kady, the company’s CEO; and Dr. Chris Nelson, Chairman of the American company Kemin, which is a partner in the project.
The event also saw the participation of several prominent officials, including deputy ministers and representatives from the health, pharmaceutical, and investment sectors, along with delegations from international organizations such as the World Health Organization, representatives from the U.S. Embassy, the Ambassador of Rwanda, as well as representatives from several Arab and international companies, university experts, and journalists.
In his speech during the ceremony, Dr. Magdy El-Sayed confirmed that these expansions fall within MEVAC’s strategy to provide safe, effective veterinary vaccines of global quality that support food security and animal health, and therefore human health. He pointed out that the new research and development center—equipped with advanced laboratories adhering to BSL-3 and BSL-2 standards—is a central pillar in developing new generations of vaccines, enhancing the company’s ability to innovate and expand into global markets.
For his part, Dr. Ahmed El-Kady, the company’s CEO, explained that MEVAC plans to invest an additional EGP 2 billion during 2026 and 2027 in advanced production facilities and technologies. This will further strengthen the company’s global leadership and enable it to meet increasing market demands. He indicated that the company aims to reach more than 90 countries by 2030, with annual export values exceeding $100 million.
Currently, MEVAC is working on developing more than 70 innovative vaccines over the next five years using the latest biotechnological techniques, such as vector-based and genetically engineered vaccines, as well as mRNA vaccines—a groundbreaking step in the Middle East and Africa. Through this, the company seeks to solidify its global standing as a scientific and innovative institution in the field of animal health.
The new innovation center, located in Building No. 3 of the industrial complex, is considered one of the company’s most important centers of excellence. It contributes to improving production efficiency and ensuring the highest quality standards, allowing MEVAC to expand its competitiveness both regionally and internationally.
At the end of the ceremony, Dr. Magdy El-Sayed emphasized that enhancing production and scientific capabilities is not a goal in itself, but rather a means to provide more efficient solutions to address veterinary health challenges. He affirmed MEVAC’s commitment to working with its partners inside and outside Egypt to build an integrated health system, where humans are the ultimate beneficiaries through improved animal health and sustainable food security.
It is worth noting that MEVAC is an Egyptian-American company founded in 2011, specialized in the production and distribution of veterinary vaccines for poultry, ruminants, and aquaculture. It owns a highly developed infrastructure that includes four main production lines spread across several sites in Egypt and is renowned for its excellence in research, development, and scientific innovation. This has enabled it to gain the trust of both local and international markets in more than 42 countries around the world.
Source: akhbarelyom.com